Blake J Cochran,Thomas W King,Kevin Chemello,Shane R Thomas,Kerry-Anne Rye
{"title":"HDL metabolism and function in diabetes mellitus.","authors":"Blake J Cochran,Thomas W King,Kevin Chemello,Shane R Thomas,Kerry-Anne Rye","doi":"10.1038/s41574-025-01176-y","DOIUrl":null,"url":null,"abstract":"Epidemiological studies have identified an inverse association of high-density lipoprotein (HDL) cholesterol with cardiovascular risk. Preclinical studies have shown that HDLs also exhibit cardioprotective functions in cultured cells and animal models. However, large, randomized, placebo-controlled clinical trials of HDL-raising agents have failed to reduce cardiovascular events in humans. Despite this negative outcome, glycaemic control was considerably improved in the patients with type 2 diabetes mellitus who were recruited into these trials. This finding indicated that HDLs might have anti-diabetic functions. This was shown to be the case in cell studies and animal studies, which have established that HDLs and apolipoprotein A1, the main HDL apolipoprotein, improve pancreatic β-cell function and increase insulin sensitivity. On the other hand, diabetes mellitus adversely affects the structure, anti-diabetic functions and cardioprotective functions of HDLs. These complex, closely linked relationships, which are undoubtedly worthy of further investigation, form the focus of this Review.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"221 4 1","pages":""},"PeriodicalIF":40.0000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41574-025-01176-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Epidemiological studies have identified an inverse association of high-density lipoprotein (HDL) cholesterol with cardiovascular risk. Preclinical studies have shown that HDLs also exhibit cardioprotective functions in cultured cells and animal models. However, large, randomized, placebo-controlled clinical trials of HDL-raising agents have failed to reduce cardiovascular events in humans. Despite this negative outcome, glycaemic control was considerably improved in the patients with type 2 diabetes mellitus who were recruited into these trials. This finding indicated that HDLs might have anti-diabetic functions. This was shown to be the case in cell studies and animal studies, which have established that HDLs and apolipoprotein A1, the main HDL apolipoprotein, improve pancreatic β-cell function and increase insulin sensitivity. On the other hand, diabetes mellitus adversely affects the structure, anti-diabetic functions and cardioprotective functions of HDLs. These complex, closely linked relationships, which are undoubtedly worthy of further investigation, form the focus of this Review.
期刊介绍:
Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.